tax1bp1a Antibody

What is TAX1BP1 and why is it significant for immunological research?

TAX1BP1 (Tax1 Binding Protein 1) is a multifunctional protein initially identified as a binding partner for the HTLV-1 Tax1 protein. It plays crucial roles in regulating immunity through several mechanisms: it interacts with TNFAIP3 (A20) to inhibit TNF-induced apoptosis, participates in inflammatory signaling pathway inhibition, and functions as a macroautophagy receptor facilitating xenophagic clearance of pathogenic bacteria such as Salmonella typhimurium and Mycobacterium tuberculosis . Recent research has revealed its novel function in the presentation of endogenous viral antigens to CD4+ T cells, highlighting its importance in adaptive immunity . TAX1BP1 significantly influences the diversity and affinity of MHC-II ligands, making it an important target for immunological studies focused on antigen presentation and T cell activation mechanisms . The protein also recruits A20/TNFAIP3 to ubiquitinated signaling proteins TRAF6 and RIPK1, leading to their deubiquitination and disruption of IL-1 and TNF-induced NF-kappa-B signaling pathways .

What are the key characteristics of available TAX1BP1 antibodies?

TAX1BP1 antibodies are available with various specifications designed for different experimental applications. Commercially available antibodies target different epitopes within the TAX1BP1 protein structure and offer the following characteristics:

Most TAX1BP1 antibodies detect the full-length protein at approximately 92 kDa, though this may vary depending on post-translational modifications and splice variants . When selecting an antibody, researchers should consider the specific region of interest in the TAX1BP1 protein and the intended experimental application to ensure optimal results.

What optimization steps are necessary for Western blotting with TAX1BP1 antibodies?

Successful Western blotting for TAX1BP1 requires careful optimization due to its relatively high molecular weight (approximately 92 kDa) and potential post-translational modifications. The following methodological approach is recommended:

• Sample Preparation: Extract protein using RIPA buffer supplemented with protease inhibitors. For studying ubiquitination-dependent functions of TAX1BP1, include deubiquitinase inhibitors such as N-ethylmaleimide .

• Gel Selection: Use 8% polyacrylamide gels for optimal separation of the 92 kDa TAX1BP1 protein from other cellular proteins.

• Transfer Conditions: For large proteins like TAX1BP1, extend transfer time (>1 hour) or use a wet transfer system with lower current to ensure complete transfer.

• Antibody Dilution: A typical dilution of 1:1000 is recommended for primary antibody incubation, though optimization may be necessary based on the specific antibody used .

• Blocking and Washing: Use 5% non-fat milk in TBST for blocking and thorough washing (3-5 times, 5-10 minutes each) to minimize background.

• Positive Controls: Include cell lines known to express TAX1BP1, such as HeLa or HEK293 cells, as positive controls for validation .

• Verification Strategy: Confirm specificity using siRNA knockdown experiments to demonstrate reduced or absent signal in TAX1BP1-depleted samples.

This optimization workflow ensures reliable detection of TAX1BP1 in Western blotting applications while minimizing non-specific signals that could complicate interpretation.

How can researchers investigate TAX1BP1's role in MHC-II-restricted antigen presentation?

Investigating TAX1BP1's role in MHC-II-restricted antigen presentation requires sophisticated experimental approaches that capture its interactions with MHC-II pathway components. Based on recent research findings, the following methodological workflow is recommended:

• RNA Interference Studies: Implement siRNA-mediated TAX1BP1 silencing followed by assessment of endogenous antigen presentation to CD4+ T cells. This approach has revealed that TAX1BP1 silencing substantially impairs MHC-II-restricted antigen presentation .

• Antigen Loading Assays: Utilize model viral antigens (e.g., HIV-Gag, pp65 from HCMV) or constructs targeting antigens to phagophores (HIV-Gag fused to LC3) to assess how TAX1BP1 affects antigen processing through autophagy-dependent or independent pathways .

• Immunopeptidomics: Employ mass spectrometry-based approaches to analyze the MHC-II peptide repertoire in the presence or absence of TAX1BP1. This technique has demonstrated that TAX1BP1 expression significantly influences both the diversity and affinity of MHC-II ligands .

• Vesicular Trafficking Analysis: Implement confocal or super-resolution microscopy to track the positioning and morphology of MHC-II+ compartments, lysosomes, and autophagosomes in TAX1BP1-sufficient versus TAX1BP1-deficient cells .

• Protein Interaction Studies: Conduct co-immunoprecipitation experiments combined with mass spectrometry to identify TAX1BP1 binding partners involved in antigen presentation, which has successfully identified calnexin (CANX) as a key interacting protein .

• CD74/Invariant Chain Stability Assessment: Monitor CD74 degradation kinetics using pulse-chase experiments or Western blot analysis in cells with manipulated TAX1BP1 levels to establish the connection between TAX1BP1, CANX, and CD74 stability .

This comprehensive experimental approach allows for detailed characterization of how TAX1BP1 influences antigen presentation through effects on MHC-II molecule trafficking, loading, and function.

What technical considerations should be addressed when using TAX1BP1 antibodies for immunoprecipitation?

Immunoprecipitation (IP) studies with TAX1BP1 antibodies require specific technical considerations to maintain protein-protein interactions while achieving efficient enrichment. The following methodological guidelines should be considered:

• Antibody Selection: Use TAX1BP1 antibodies specifically validated for IP applications, such as the D1D5 rabbit monoclonal antibody, which has been demonstrated to effectively immunoprecipitate endogenous TAX1BP1 .

• Lysis Buffer Optimization: For studying TAX1BP1 interactions with TNFAIP3 or CANX, use mild lysis conditions with buffers containing:

  • 1% NP-40 or 0.5% Triton X-100

  • Low salt concentration (150mM NaCl)

  • Protease and phosphatase inhibitors

  • 10mM N-ethylmaleimide for preserving ubiquitinated targets

• Antibody Concentration: Use a 1:100 dilution of the TAX1BP1 antibody for optimal IP results, adjusting based on experimental requirements and antibody potency .

• Pre-clearing Strategy: Pre-clear lysates with protein A/G beads to reduce non-specific binding, particularly important when studying low-abundance interactions.

• Controls: Include appropriate controls:

  • IgG isotype control to identify non-specific binding

  • Input sample (typically 5-10% of IP material)

  • TAX1BP1-depleted cell lysate as a negative control

• Elution Conditions: Use gentle elution conditions (competitive elution with peptide or low pH glycine buffer) to preserve interaction partners for downstream analysis.

• Confirmation Strategy: Validate results using reciprocal IP experiments, where the suspected interacting partner is immunoprecipitated and TAX1BP1 is detected in the precipitate.

These technical considerations enable researchers to effectively investigate TAX1BP1's interactions with key partners such as CANX, which has been shown to play a critical role in CD74 stability and MHC-II-restricted antigen presentation .

How can researchers differentiate between TAX1BP1's autophagy-related functions and its roles in immune signaling?

Differentiating between TAX1BP1's dual roles in autophagy and immune signaling requires strategic experimental approaches that can distinguish between these interconnected functions. The following methodological workflow is recommended:

• Domain-Specific Mutant Analysis: Generate and express TAX1BP1 constructs with mutations in key functional domains:

  • LC3-interacting region (LIR) mutations to disrupt autophagy functions

  • SKICH domain mutations to affect ubiquitin-binding properties

  • Zinc finger domain mutations to impair interactions with signaling molecules

• Autophagy Flux Assessment: Monitor autophagy markers (LC3-II, p62/SQSTM1) in the presence of TAX1BP1 wild-type versus mutant constructs, with and without lysosomal inhibitors (e.g., Bafilomycin A1) to assess autophagy flux.

• Selective Pathway Activation:

  • For immune signaling: Stimulate cells with TNF-α or IL-1β and assess NF-κB activation

  • For autophagy: Induce autophagy through starvation or rapamycin treatment

  • Compare TAX1BP1's involvement in both contexts using the same experimental system

• Xenophagy Assays: Utilize bacterial infection models (e.g., Salmonella typhimurium) to assess TAX1BP1's role in pathogen clearance through autophagy mechanisms, which is distinct from its immune signaling functions .

• Biochemical Separation: Employ subcellular fractionation to physically separate autophagosome-associated TAX1BP1 from cytosolic signaling complexes, then analyze each fraction for specific interacting partners.

• Temporal Analysis: Implement time-course experiments to determine whether TAX1BP1's roles in autophagy and immune signaling occur sequentially or simultaneously after stimulus application.

• Proximity Ligation Assays: Use in situ proximity ligation to visualize and quantify TAX1BP1's interactions with autophagy machinery versus immune signaling components within intact cells.

This multifaceted approach enables researchers to distinguish between TAX1BP1's roles in the xenophagic clearance of pathogenic bacteria and its functions in inhibiting inflammatory signaling pathways through interactions with signaling molecules like TNFAIP3 .

What are common challenges in TAX1BP1 antibody experiments and how can they be resolved?

Researchers working with TAX1BP1 antibodies frequently encounter several technical challenges that can affect experimental outcomes. The following troubleshooting guide addresses these issues with methodological solutions:

When interpreting results, it's crucial to consider that TAX1BP1's multiple functional domains may be differentially accessible depending on its interaction partners and post-translational modifications, which can affect antibody recognition.

How can researchers optimize immunofluorescence protocols for studying TAX1BP1's subcellular localization?

Visualizing TAX1BP1's subcellular localization through immunofluorescence requires specific protocol optimizations to accurately capture its distribution in autophagy-related structures and immune signaling complexes. The following methodological approach is recommended:

• Fixation Method Selection:

  • For general localization: 4% paraformaldehyde for 10-15 minutes at room temperature

  • For autophagosome association studies: Methanol fixation (-20°C, 10 minutes) to preserve LC3-positive structures

  • Avoid over-fixation which can mask epitopes in protein-dense regions

• Permeabilization Optimization:

  • Use 0.1-0.3% Triton X-100 for balanced permeabilization

  • For membrane-associated TAX1BP1 pools, consider gentler permeabilization with 0.1% saponin

• Blocking Strategy:

  • Implement dual blocking with 5% normal serum (matching secondary antibody host) plus 2% BSA

  • Include 0.1% Tween-20 in blocking solution to reduce non-specific binding

• Primary Antibody Incubation:

  • Dilute antibody in blocking buffer (typically 1:100 to 1:500)

  • Extend incubation time (overnight at 4°C) to improve signal-to-noise ratio

  • For co-localization studies with CANX, ensure epitope compatibility between antibodies

• Visualization Enhancement:

  • Implement tyramide signal amplification for low-abundance TAX1BP1 pools

  • Use super-resolution microscopy (SIM, STED, or STORM) for detailed co-localization analyses with vesicular markers

• Co-localization Controls:

  • Include markers for relevant compartments:

    • LC3 for autophagosomes

    • LAMP1 for lysosomes

    • HLA-DM for MHC-II compartments

    • CANX for ER localization

  • Use Pearson's correlation coefficient or Manders' overlap coefficient for quantification

• Validation Strategy:

  • Confirm specificity with siRNA knockdown controls

  • Verify localization patterns with GFP-tagged TAX1BP1 constructs in live cells

This optimized approach enables accurate visualization of TAX1BP1's association with late endosomes, lysosomes, and autophagosomes, which is critical for understanding its role in MHC-II-restricted antigen presentation .

How can TAX1BP1 antibodies be employed to investigate its role in viral pathogenesis?

TAX1BP1's interactions with viral proteins and its influence on immune responses make it a valuable target for studying virus-host interactions. The following methodological approach can help researchers explore these connections:

• Viral Infection Models: Establish cellular models infected with relevant viruses (e.g., HTLV-1, HIV-1, HCMV) and employ TAX1BP1 antibodies to track its recruitment to viral replication compartments or its sequestration by viral factors .

• Proximity-Based Interaction Mapping: Implement BioID or APEX2 approaches with TAX1BP1 as the bait protein in infected versus uninfected cells to identify virus-induced changes in its interactome.

• Phosphorylation Status Analysis: Use phospho-specific antibodies or phospho-enrichment followed by TAX1BP1 immunoblotting to determine how viral infection alters TAX1BP1's post-translational modification state.

• MHC-II Presentation Pathway: Investigate how viral proteins interfere with TAX1BP1's role in antigen presentation by examining:

  • CD74/invariant chain processing and stability

  • HLA-DM trafficking and localization

  • MHC-II compartment positioning

• CANX-TAX1BP1-CD74 Axis: Explore whether viruses target the interaction between TAX1BP1 and calnexin to disrupt CD74 stability and consequently impair MHC-II-restricted presentation of viral antigens .

• Autophagy Manipulation: Assess how viral autophagy modulators affect TAX1BP1's function in selective autophagy and antigen presentation, particularly focusing on viral proteins known to interfere with autophagy pathways.

This investigative framework enables researchers to determine whether TAX1BP1 is targeted by viral immune evasion strategies, potentially opening new avenues for antiviral therapeutic development.

What experimental approaches can identify novel TAX1BP1 post-translational modifications affecting its function?

TAX1BP1's functions are likely regulated by diverse post-translational modifications (PTMs) that influence its protein interactions and subcellular localization. The following methodological workflow can help researchers identify and characterize these regulatory PTMs:

• Mass Spectrometry-Based PTM Mapping:

  • Immunoprecipitate endogenous TAX1BP1 using validated antibodies

  • Perform tryptic digestion followed by LC-MS/MS analysis

  • Implement enrichment strategies for specific PTMs:

    • Phosphopeptide enrichment using TiO2 or IMAC

    • Ubiquitinated peptide enrichment using K-ε-GG antibodies

    • Acetylated peptide enrichment using anti-acetyl lysine antibodies

• Stimulus-Dependent PTM Analysis:

  • Compare TAX1BP1 PTM profiles under various conditions:

    • Basal versus TNF-α stimulation

    • Normal versus autophagy-inducing conditions

    • Unstimulated versus pathogen-infected cells

• Site-Specific Mutant Generation:

  • Create TAX1BP1 constructs with point mutations at identified PTM sites

  • Assess how these mutations affect:

    • Interaction with binding partners (CANX, TNFAIP3)

    • Autophagy receptor function

    • MHC-II antigen presentation efficiency

• PTM-Specific Antibody Development:

  • Generate antibodies against major PTM sites

  • Validate using wild-type versus mutant constructs

  • Apply to track modification status under different cellular conditions

• Enzyme Identification:

  • Conduct targeted screens to identify kinases, phosphatases, ubiquitin ligases, or deubiquitinases that regulate TAX1BP1

  • Validate through enzyme inhibition/activation and direct interaction studies

This comprehensive approach can reveal how PTMs regulate TAX1BP1's dual roles in autophagy and immune signaling, potentially identifying targetable regulatory nodes for therapeutic intervention in immune disorders.

What methodological considerations are important when studying TAX1BP1's interactions with the calnexin-CD74 axis?

Recent research has unveiled TAX1BP1's interaction with calnexin (CANX) as a critical regulator of CD74 stability and consequently MHC-II antigen presentation . Studying this interaction pathway requires specific methodological considerations:

• Interaction Domain Mapping:

  • Use truncated TAX1BP1 constructs to identify the precise region interacting with CANX

  • Focus on the cytosolic tail of CANX, which has been demonstrated to interact with TAX1BP1

  • Employ peptide arrays or yeast two-hybrid assays to define minimal binding motifs

• Stabilization of Transient Interactions:

  • Implement crosslinking strategies before immunoprecipitation

  • Consider proximity-dependent labeling approaches (BioID, APEX)

  • Use appropriate lysis conditions that preserve membrane-associated complexes

• Three-Way Interaction Analysis:

  • Investigate whether TAX1BP1-CANX-CD74 form a ternary complex or compete for binding

  • Employ sequential immunoprecipitation (TAX1BP1 → CANX → CD74)

  • Conduct in vitro reconstitution with purified components

• CD74 Degradation Kinetics:

  • Implement pulse-chase experiments to measure CD74 half-life

  • Compare degradation rates in conditions with:

    • Normal TAX1BP1 levels

    • TAX1BP1 silencing

    • TAX1BP1 overexpression

    • CANX manipulation

• Visualization Strategy:

  • Use three-color immunofluorescence to simultaneously track TAX1BP1, CANX, and CD74

  • Employ super-resolution microscopy to resolve subcellular co-localization patterns

  • Implement live-cell imaging with fluorescently tagged proteins to track dynamic interactions

• Functional Readouts:

  • Measure MHC-II surface levels by flow cytometry

  • Assess presentation of model antigens to CD4+ T cells

  • Quantify the diversity and affinity of MHC-II-associated peptides by immunopeptidomics

This methodological framework enables detailed characterization of how TAX1BP1 influences CD74 stability through CANX interaction, providing insights into a previously unrecognized mechanism regulating MHC-II-restricted antigen presentation.